Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Appointed director
Quarterly results
CC transcript
HUMAN GENOME SCIENCES INC (HGSI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2012 8-K Quarterly results
08/01/2012 8-K Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an...
07/16/2012 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Other Events, Financial Sta...
Docs: "Agreement and Plan of Merger, among Human Genome Sciences, Inc., GlaxoSmithKline plc and H. Acquisition Corp",
"Amendment No. 1 to Rights Agreement, between Human Genome Sciences, Inc. and American Stock Transfer & Trust Company, LLC, as Rights Agent",
"GSK to acquire Human Genome Sciences for US$14.25 per share in cash"
05/17/2012 8-K Form 8-K - Current report
05/16/2012 8-K Submission of Matters to a Vote of Security Holders
04/24/2012 8-K Quarterly results
Docs: "Investor Contact:",
"Slide Presentation relating to earnings conference call"
04/19/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "HUMAN GENOME SCIENCES ANNOUNCES UNSOLICITED OFFER FROM GLAXOSMITHKLINE; HGS BOARD OF DIRECTORS AUTHORIZES EXPLORATION OF STRATEGIC ALTERNATIVES"
02/27/2012 8-K Form 8-K - Current report
01/09/2012 8-K Form 8-K - Current report
11/16/2011 8-K Form 8-K - Current report
11/10/2011 8-K Form 8-K - Current report
11/07/2011 8-K Form 8-K - Current report
10/25/2011 8-K Quarterly results
Docs: "Media Contacts: Investor Contacts:"
09/30/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "NICE draft guidance denies funding for lupus treatment Benlysta on the NHS Draft guidance issued today by the National Institute for Health and Clinical Excellence does not recommend Benlysta ® for patients with active autoantibody positive systemic lupus erythematosus in England and Wales because it does not consider it to be a cost-effective use of NHS resources. Lupus is a chronic, auto-immune disease that disproportionately affects women of child bearing age from ethnic minority backgrounds. If left untreated, disease activity can cause severe, debilitating fatigue, fever, joint pain and long-term organ damage. Systemic lupus erythematosus affects approximately 20,000 people in England and Wales. i,ii There has been little therapeutic innovation in treatments for lupus for many years. ..."
09/08/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Corporate Update Presentation"
08/01/2011 8-K Form 8-K - Current report
07/21/2011 8-K Quarterly results
Docs: "Media Contacts: Investor Contacts:"
07/14/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "GLAXOSMITHKLINE AND HUMAN GENOME SCIENCES RECEIVE EUROPEAN AUTHORIZATION FOR BENLYSTA ®"
05/12/2011 8-K/A Form 8-K - Current report [amend]
04/28/2011 8-K Form 8-K - Current report
04/14/2011 8-K Investor presentation
Docs: "Media Contacts: Investor Contacts:",
"Slide Presentation"
03/14/2011 8-K Form 8-K - Current report
02/24/2011 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Media Contacts: Investor Contacts:"
01/21/2011 8-K Form 8-K - Current report
01/10/2011 8-K Form 8-K - Current report
12/14/2010 8-K Appointed a new director
11/08/2010 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Slide Presentation"
10/27/2010 8-K Form 8-K - Current report
10/06/2010 8-K Form 8-K - Current report
09/13/2010 8-K Form 8-K - Current report
07/22/2010 8-K Form 8-K - Current report
05/24/2010 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Amended and Restated By-Laws, as of May 20, 2010",
"Certificate of Elimination of Series A Junior Participating Preferred Stock"
04/29/2010 8-K Quarterly results
Docs: "HUMAN GENOME SCIENCES ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS AND KEY DEVELOPMENTS"
03/10/2010 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy